ZURICH, Sept 17 (Reuters) - Novartis's
investigational multiple sclerosis drug cut the risk of
disability progression in patients with a tough-to-treat form of
the disease versus a placebo, the Swiss company said on
Saturday, citing a new analysis of a late-stage trial.
Read more
No comments:
Post a Comment